Literature DB >> 27893351

Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.

Claudio Cerchione1, Giuseppe Cerciello1, Simona Avilia1, Roberta Della Pepa1, Novella Pugliese1, Marco Picardi1, Lucio Catalano1, Fabrizio Pane1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27893351      PMCID： PMC5770312          DOI： 10.2450/2016.0137-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  18 in total

1.  Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.

Authors:  Arunee Jetsrisuparb; Patcharee Komvilaisak; Surapon Wiangnon; Charoon Jetsrisuparb
Journal:  J Pediatr Hematol Oncol       Date:  2010-07       Impact factor: 1.289

Review 2.  Efficacy and safety of deferasirox in myelodysplastic syndromes.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Ann Hematol       Date:  2013-02-17       Impact factor: 3.673

Review 3.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

4.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

Authors:  B A Davis; J B Porter
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

5.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

6.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Authors:  Christian Rose; Sabine Brechignac; Dominique Vassilief; Laurent Pascal; Aspasia Stamatoullas; Agnes Guerci; Dalila Larbaa; François Dreyfus; Odile Beyne-Rauzy; Marie Pierre Chaury; Lydie Roy; Stephane Cheze; Pierre Morel; Pierre Fenaux
Journal:  Leuk Res       Date:  2010-02-02       Impact factor: 3.156

7.  Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

Authors:  Ashutosh Lal; John Porter; Nancy Sweeters; Vivian Ng; Patricia Evans; Lynne Neumayr; Gregory Kurio; Paul Harmatz; Elliott Vichinsky
Journal:  Blood Cells Mol Dis       Date:  2012-11-11       Impact factor: 3.039

8.  Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.

Authors:  Judith Neukirchen; Frank Fox; Andrea Kündgen; Kathrin Nachtkamp; Corinna Strupp; Rainer Haas; Ulrich Germing; Norbert Gattermann
Journal:  Leuk Res       Date:  2012-05-06       Impact factor: 3.156

9.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Authors:  John Porter; Renzo Galanello; Giuseppe Saglio; Ellis J Neufeld; Elliott Vichinsky; Maria Domenica Cappellini; Nancy Olivieri; Antonio Piga; Melody J Cunningham; Denis Soulières; Norbert Gattermann; Gilbert Tchernia; Johan Maertens; Patricia Giardina; Janet Kwiatkowski; Giovanni Quarta; Michael Jeng; Gian Luca Forni; Michael Stadler; Holger Cario; Louisette Debusscher; Matteo Della Porta; Mario Cazzola; Peter Greenberg; Giuliana Alimena; Bertrand Rabault; Insa Gathmann; John Malcolm Ford; Daniele Alberti; Christian Rose
Journal:  Eur J Haematol       Date:  2007-11-17       Impact factor: 2.997

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.